4th Clinical Microbiology and Microbial Genomics Conference

Biography

Biography: Dr. John G Thomas

Abstract

Chronic wounds are one of the most costly health care issues, affecting 6.5 million patients at an annual cost of US $25 billion, focusing on a growing aged population . Multiple interventions emphasizing silver gauze have not altered QOL issues or reduced significant collateral damage of MDR sepsis and C. difficile. In 2012, we introduced and evaluated the SMarT probiotic matrix concept, where a bi-phasic strategy harmonizes an ecologic approach of Minimal Intervention (MI) disruption while restoring microbial architecture and tissue engineering. The emergence of Probiotic therapy had been catalyzed by recent advances in microbiota and metagenomics, particularly dentistry where we initially evaluated probioitics in endodontics . In the Discovery ( in vitro) phase 2013/4, 3 pools of probiotics were evaluated for anti-biofilm, anti-planktonic activity, ultimately creating a “Designer Symbiotic” combination against 3 wound pathogens: Staph aureus, C. albicans and P aeruginosa. In Application (in vivo) phase ( 2015/16), the “Designer Symbiotic” is being evaluated using a rabbit wound mode infected with the same strains , complimenting bio-burden wound reduction and site closure/tissue regeneration bellow “critical colonization “ with a combined silver dressing/silver gels “suite platform” enforcing “site-saturation”. The wound/tissue environment will be strengthened utilizing delivery of the Symbiotic via a bio-degradable, bio-plastic scaffolding with barrier activity enhanced by form fitting gauze individually constructed with 3-D Printing using plasma as the ink.